| 王 玲,张 新,白 云,周玉红,王世蓉.唑来膦酸注射液联合骨肽注射液治疗绝经后骨质疏松症的临床疗效及安全性分析[J].,2019,19(5):915-918 |
| 唑来膦酸注射液联合骨肽注射液治疗绝经后骨质疏松症的临床疗效及安全性分析 |
| Clinical Efficacy and Safety of Zoledronic Acid Injection Combined with Bone Peptide Injection in the Treatment of Postmenopausal Osteoporosis |
| 投稿时间：2018-11-08 修订日期：2018-11-30 |
| DOI：10.13241/j.cnki.pmb.2019.05.027 |
| 中文关键词: 唑来膦酸注射液 骨肽注射液 骨质疏松症 疗效 安全性 |
| 英文关键词: Zoledronic acid injection Bone peptide injection Osteoporosis Efficacy Safety |
| 基金项目:国家自然科学基金项目(81370123) |
|
| 摘要点击次数: 696 |
| 全文下载次数: 494 |
| 中文摘要: |
| 摘要 目的：研究唑来膦酸注射液联合骨肽注射液治疗绝经后骨质疏松症的临床效果以及安全性。方法：选择2014年1月～2018年1月我院收治的100例绝经后骨质疏松症患者，将其随机分为两组。对照组采用静脉滴注唑来膦酸注射液5 mg一次，观察组在对照组基础上静脉注射骨肽注射液，每次30 mg，每天1次。治疗6个月后，检测并比较两组治疗前后的骨代谢指标(血清骨特异性碱性磷酸酶(BAP)、甲状旁腺素(PTH)、血磷(P)、血钙(Ca)和碱性磷酸酶(ALP))以及骨转换指标(骨钙素(OC)和Ⅰ型胶原交联C-末端肽(CTX-1))的变化及不良反应的发生情况。结果：治疗后，观察组总有效率明显高于对照组(P<0.05)；两组血清ALP、PTH以及BAP等骨代谢指标均较治疗前明显降低(P<0.05)，且观察组以上指标明显低于对照组(P<0.05)；两组的OC均较治疗前明显升高(P<0.05)，CTX-1均较治疗前明显降低(P<0.05)，且观察组的骨转换指标改善的程度较对照组更为明显(P<0.05)。观察组的不良反应发生率为8.00 %(4/50)，明显低于对照组[18.00 %(9/50)](P<0.05)。结论：唑来膦酸注射液联合骨肽注射液治疗绝经后骨质疏松症的效果明显优于单独使用唑来膦酸注射液，其可以显著改善患者的骨代谢及骨转换状态，且安全性更高。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the clinical efficacy and safety of zoledronic acid injection combined with bone peptide in- jection in the treatment of postmenopausal osteoporosis. Methods: 100 cases of patients with postmenopausal osteoporosis admitted to our hospital from January 2014 to January 2018 were randomly divided into two groups. The control group was given zoledronic acid in- jection 5 mg once, while the observation group was given bone peptide injection 30 mg once a day on the basis of the control group. After 6 months of treatment, the changes of bone metabolism indexes (serum bone specific alkaline phosphatase (BAP), parathyroid hormone (PTH), blood phosphorus (P), blood calcium (Ca) and alkaline phosphatase (ALP), bone turnover indexes (OC) and collagen type I cross-linked C-terminal peptide (CTX-1) and adverse reactions were detected and compared between the two groups before and after treatment. Results: After treatment, the total effective rate of observation group was significantly higher than that of the control group(P< 0.05); the serum ALP, PTH and BAP of both groups were significantly lower than those before treatment(P<0.05), and the above indexes of observation group were significantly lower than those of the control group(P<0.05); the OC of the two groups were significantly higher than before treatment(P<0.05), the CTX-1 was significantly lower than before treatment(P<0.05). The improvement of bone turnover in- dex in the observation group was more significant than that in the control group(P<0.05). The incidence of adverse reactions in the ob- servation group was 8%(4/50), which was significantly lower than that in the control group [18.00% (9/50)] (P<0.05). Conclusion: Zole- dronic acid injection combined with bone peptide injection is significantly effective than zoledronic acid injection alone in the treatment of postmenopausal osteoporosis, which can significantly improve bone metabolism and bone turnover with higher safety. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
